Clinical Trials - ONCT-534 Phase 1/2 study for advanced prostate cancer shows no dose-limiting toxicities; 1200 mg cohort enrolled and treated, with initial data expected in Q3 2024[1] - ONCT-808 Phase 1/2 study for relapsed or refractory aggressive B-cell lymphoma is open for enrollment, with clinical data update anticipated in Q4 2024[2] - The company has implemented protocol changes in the ONCT-808 study to enhance patient monitoring and evaluate lower doses[2] - ONCT-534 and ONCT-808 are part of Oncternal's strategy to address critical unmet medical needs in oncology[4] Financial Performance - Cash, cash equivalents, and short-term investments totaled $21.4 million as of June 30, 2024, with a cash runway projected into Q1 2025[1] - Grant revenue for Q2 2024 was $0.8 million, while total operating expenses were $9.7 million, including $1.4 million in non-cash stock-based compensation[3] - Net loss for Q2 2024 was $8.6 million, or $2.89 per share, with approximately 3.0 million shares of common stock outstanding[3] - Research and development expenses for Q2 2024 totaled $6.6 million, while general and administrative expenses were $3.1 million[3] - Total assets as of June 30, 2024, were $23.9 million, down from $36.7 million as of December 31, 2023[7] - Accumulated deficit increased to $214.7 million as of June 30, 2024, compared to $197.8 million at the end of 2023[7]
Oncternal Therapeutics(ONCT) - 2024 Q2 - Quarterly Results